← Leaderboards
Jason Stephen Meyer
Indiana University Indianapolis
$10,504,585
Attributed
$19,594,032
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.4M · FY2015–25$10M$7.5M$5M$2.5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,929,048 · 11
By mechanism
U24$7,031,142 · 1
R01$6,753,491 · 4
U54$5,102,752 · 3
RF1$3,224,075 · 1
R21$817,588 · 2
Top collaborators
- Brad Fortune8 shared
- Yvonne Ou8 shared
- Benjamin M Sivyer6 shared
- Gareth R Howell4 shared
- Bruce T Lamb4 shared
- Donna M Martin3 shared
- Ann C Morris3 shared
- Michael L Schulte2 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Benjamin M Sivyer$4,300,195
- Alon Harris$1,562,726
- Laura Cracco$670,029
- Benjamin Ryskeldi-Falcon$670,029
- Kaylee Tutrow$82,606
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainAlzheimer&AposCellsNeuronsInduced Pluripotent Stem CellAstrocytesNeuroinflammationRetinaBlindnessNeurogliaGlaucomaRetinal Ganglion CellsAffectMutationPhenotypeCell TypeAxonNerve DegenerationGeneticCell Differentiation ProcessCoculture TechniquesCharacteristicsExperimental StudyIn Vitro
Grant awards (31)
Microphysiological systems to Advance Precision medicine for Alzheimer's Disease and Related Dementias (MAP-AD)$3,335,016
U54 · FY2025 · AG · contact PI
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$1,283,906
U24 · FY2025 · EY · contact PI
Microphysiological systems to Advance Precision medicine for Alzheimer's Disease and Related Dementias (MAP-AD)$1,173,352
U54 · FY2025 · AG · contact PI
Functions of chromatin remodeler Chd7 in retinal cell development$614,672
R01 · FY2025 · EY
Microphysiological systems to Advance Precision medicine for Alzheimer's Disease and Related Dementias (MAP-AD)$594,384
U54 · FY2025 · AG · contact PI
Establishing a human cellular model of retinal ganglion cell compartmentalization in neurodegeneration and neuroinflammation$400,591
R01 · FY2025 · EY · contact PI
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$1,328,663
U24 · FY2024 · EY · contact PI
Deciphering the role of CX3CR1 in Modulating Mechanisms of Amyloid driven Neurodegeneration in Alzheimer's Disease$746,243
R01 · FY2024 · AG
Functions of chromatin remodeler Chd7 in retinal cell development$614,672
R01 · FY2024 · EY
Establishing a human cellular model of retinal ganglion cell compartmentalization in neurodegeneration and neuroinflammation$400,591
R01 · FY2024 · EY · contact PI
Targeting P2RX7 Signaling as a Biomarker for ADRD$248,796
R21 · FY2024 · AG
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$145,254
U24 · FY2024 · EY · contact PI
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$1,339,355
U24 · FY2023 · EY · contact PI
Functions of chromatin remodeler Chd7 in retinal cell development$640,132
R01 · FY2023 · EY
Establishing a human cellular model of retinal ganglion cell compartmentalization in neurodegeneration and neuroinflammation$400,591
R01 · FY2023 · EY · contact PI
Targeting P2RX7 Signaling as a Biomarker for ADRD$222,816
R21 · FY2023 · AG
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$93,412
U24 · FY2023 · EY · contact PI
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$93,412
U24 · FY2023 · EY · contact PI
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$1,353,535
U24 · FY2022 · EY · contact PI
Establishing a human cellular model of retinal ganglion cell compartmentalization in neurodegeneration and neuroinflammation$388,574
R01 · FY2022 · EY · contact PI
Deciphering the role of CX3CR1 in Modulating Mechanisms of Amyloid driven Neurodegeneration in Alzheimer's Disease (Diversity Supplement)$136,078
RF1 · FY2022 · AG
Overcoming Barriers to retinal ganglion cell replacement in experimental glaucoma$1,393,605
U24 · FY2021 · EY · contact PI
Establishing a human cellular model of retinal ganglion cell compartmentalization in neurodegeneration and neuroinflammation$421,591
R01 · FY2021 · EY · contact PI
Deciphering the role of CX3CR1 in Modulating Mechanisms of Amyloid driven Neurodegeneration in Alzheimer's Disease$3,087,997
RF1 · FY2020 · AG
Derivation and disease modeling of human stem cell-derived retinal ganglion cells$354,008
R01 · FY2019 · EY · contact PI
Targeting the diversity of retinal ganglion cells for replacement therapy$345,976
R21 · FY2019 · EY · contact PI
Derivation and Disease Modeling of Human Stem Cell-Derived Retinal Ganglion Cells$339,532
R01 · FY2019 · EY · contact PI
Derivation and disease modeling of human stem cell-derived retinal ganglion cells$354,241
R01 · FY2018 · EY · contact PI
Derivation and disease modeling of human stem cell-derived retinal ganglion cells$354,467
R01 · FY2017 · EY · contact PI
Derivation and disease modeling of human stem cell-derived retinal ganglion cells$354,686
R01 · FY2016 · EY · contact PI
Derivation and disease modeling of human stem cell-derived retinal ganglion cells$368,900
R01 · FY2015 · EY · contact PI